期刊名称：Annals of Agricultural and Environmental Medicine
印刷版ISSN：1232-1966
电子版ISSN：1898-2263
出版年度：2015
卷号：22
期号：2
页码：320-324
DOI：10.5604/12321966.1152087
出版社：Institute of Agricultural Medicine in Lublin
摘要：Introduction. Transplant recipients have a significantly greater incidence of cancer, compared with the general population,who are referred to immunosuppressive therapy as an additional malignancy risk factor. Therefore, there is a need to searchfor an easy in clinical practice neoplasm predictor, especially for this group of patients.Materials and methods. A group of 74 (43M and 31F; aged 46.8 ± 12 years) kidney transplant recipients was investigatedin a three-year follow-up study. During the time of observation, 7 patients were diagnosed with neoplasm (7.4 ± 1.5 yearsafter transplantation). A serum level of IL2 (ELISA test) and mRNA level of IL1beta, IL10 and TNFalfa in peripheral mononuclearblood cells – PBMCs (QRT – PCR method) were measured in every year of observation. Analysis of variances and t-Studenttest were used in groups mean comparison:N – patients developing malignant neoplasm group (24 probes);M – set of probes from patients with malignancies at the moment of diagnosis (11 probes);P – set of probes from patients before developing malignant neoplasm (10 probes);C – control group of healthy transplant recipients (31 probes).Results. Among the analyzed agents, only serum IL2 level differed between the analyzed groups, with higher values in theM compared with the P group (p<0.05) and with C group (p<0.01). There were no differences neither between N and C orP and C groups (p = 0.98), nor any correlation between IL2 and IL1b, IL2 and TNFalfa.Conclusions. The results may indicate that IL2 serum level might be consider as a useful late unspecific cancer marker,although larger studies should yield verification of this finding.
